Trial · NCT02418312
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
NCT02418312, Not applicable, Completed, Kaohsiung Veterans General Hospital.; results first posted 2019-03-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer. Trials, record NCT02418312. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02418312
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
- NCT number
- NCT02418312
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 228 participants, actual
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Conditions
- Peptic Ulcer
- Interventions
- histamine-2 receptor antagonist, Placebo
- First posted
- 2015-04-16
- Last updated
- 2019-03-11
- Results first posted
- 2019-03-11
- Limitations and caveats
- The trial was performed in a single country
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Healed Peptic Ulcer | 6 months | Follow-up endoscopy was performed at the end of the 6th month |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Healed Peptic Ulcer | 6 months | Intention to treat | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Healed Peptic Ulcer | Histamine-2 Receptor Antagonist Group | 106 | participants | ||
| Number of Participants With Healed Peptic Ulcer | Placebo Group | 101 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Histamine-2 Receptor Antagonist Group | 114 | |
| Overall Study | STARTED | Placebo Group | 114 | |
| Overall Study | COMPLETED | Histamine-2 Receptor Antagonist Group | 114 | |
| Overall Study | COMPLETED | Placebo Group | 114 | |
| Overall Study | NOT COMPLETED | Histamine-2 Receptor Antagonist Group | 0 | |
| Overall Study | NOT COMPLETED | Placebo Group | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | skin rash | Skin and subcutaneous tissue disorders | Histamine-2 Receptor Antagonist Group | 1 | 114 | 1 |
| other | skin rash | Skin and subcutaneous tissue disorders | Placebo Group | 0 | 114 | 0 |
| other | persistent dyspepsia | Gastrointestinal disorders | Histamine-2 Receptor Antagonist Group | 1 | 114 | 1 |
| other | persistent dyspepsia | Gastrointestinal disorders | Placebo Group | 2 | 114 | 2 |
| other | diarrhea | Gastrointestinal disorders | Histamine-2 Receptor Antagonist Group | 1 | 114 | 1 |
| other | diarrhea | Gastrointestinal disorders | Placebo Group | 0 | 114 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Histamine-2 Receptor Antagonist Group | 0 | 114 |
| Total, all-cause mortality | Placebo Group | 0 | 114 |
| Total, other adverse events | Histamine-2 Receptor Antagonist Group | 3 | 114 |
| Total, other adverse events | Placebo Group | 2 | 114 |
| Total, serious adverse events | Histamine-2 Receptor Antagonist Group | 0 | 114 |
| Total, serious adverse events | Placebo Group | 0 | 114 |
Source ClinicalTrials.gov
Papers23
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Histamine-2 Receptor Antagonist Group vs Placebo Group: Number of Participants With Healed Peptic Ulcer | Trial comparisons |
| Histamine-2 Receptor Antagonist Group vs Placebo Group: deaths from any cause | Trial comparisons |
| Histamine-2 Receptor Antagonist Group vs Placebo Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02418312
GET https://conductscience.org/api/trials/v1/NCT02418312/papers?page=2